These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27789676)

  • 41. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
    Kasamatsu T; Ozaki S; Saitoh T; Konishi J; Sunami K; Itagaki M; Asaoku H; Cho T; Handa H; Hagiwara S; Wakayama T; Negoro A; Takezako N; Harada N; Kuroda Y; Nakaseko C; Miyake T; Inoue N; Hata H; Shimazaki C; Ohno T; Kuroda J; Murayama T; Kobayashi T; Abe M; Ishida T; Nagura E; Shimizu K
    Hematol Oncol; 2018 Dec; 36(5):792-800. PubMed ID: 30176173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
    Song MK; Chung JS; Lee JJ; Lee JH; Song IC; Lee SM; Shin DY; Lee GW; Lee IS
    Acta Haematol; 2015; 134(1):7-16. PubMed ID: 25832367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.
    Hou ZL; Kang Y; Yang GZ; Wang Z; Wang F; Yu YX; Chen WM; Shi HZ
    Ann Hematol; 2021 Jul; 100(7):1789-1801. PubMed ID: 33715037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort study.
    Rahman M; Keegan A; Mateus J; Kim C
    Leuk Lymphoma; 2023 Feb; 64(2):388-397. PubMed ID: 36371167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
    Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
    Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.
    Kleber M; Ihorst G; Gross B; Koch B; Reinhardt H; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):541-51. PubMed ID: 23810244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
    Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
    Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
    Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years.
    Fujisawa M; Suehara Y; Fukumoto K; Takeuchi M; Matsue K
    Ann Hematol; 2016 Jan; 95(1):63-72. PubMed ID: 26499344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.
    Cohen YC; Joffe E; Benyamini N; Dimopoulos MA; Terpos E; Trestman S; Held-Kuznetsov V; Avivi I; Kastritis E
    Leuk Lymphoma; 2016; 57(6):1382-8. PubMed ID: 26727104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
    Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
    Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.
    Giri S; Huntington SF; Wang R; Zeidan AM; Podoltsev N; Gore SD; Ma X; Gross CP; Davidoff AJ; Neparidze N
    Blood Adv; 2020 May; 4(10):2245-2253. PubMed ID: 32442299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
    Mellors PW; Binder M; Ketterling RP; Greipp PT; Baughn LB; Peterson JF; Jevremovic D; Pearce KE; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2020 May; 4(10):2236-2244. PubMed ID: 32442300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk Stratification in Multiple Myeloma.
    Ooi MG; de Mel S; Chng WJ
    Curr Hematol Malig Rep; 2016 Apr; 11(2):137-47. PubMed ID: 26883334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.
    Hummel M; Hielscher T; Emde-Rajaratnam M; Salwender H; Beck S; Scheid C; Bertsch U; Goldschmidt H; Jauch A; Moreaux J; Seckinger A; Hose D
    JCO Precis Oncol; 2024 Jul; 8():e2300613. PubMed ID: 38986047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population.
    Udupa CBK; Udupa KS; Pai A; Sherigar P
    Iran J Pathol; 2020; 15(3):182-188. PubMed ID: 32754213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society.
    Abe Y; Sunami K; Yamashita T; Ueda M; Takamatsu H; Narita K; Kobayashi H; Kitadate A; Takeuchi M; Matsue K
    Oncotarget; 2019 Jan; 10(5):595-605. PubMed ID: 30728910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.
    Mosquera Orgueira A; González Pérez MS; Diaz Arias J; Rosiñol L; Oriol A; Teruel AI; Martinez Lopez J; Palomera L; Granell M; Blanchard MJ; de la Rubia J; López de la Guia A; Rios R; Sureda A; Hernandez MT; Bengoechea E; Calasanz MJ; Gutierrez N; Martin ML; Blade J; Lahuerta JJ; San Miguel J; Mateos MV;
    Blood Cancer J; 2022 Apr; 12(4):76. PubMed ID: 35468898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.